



June 10, 2021

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E),
Mumbai - 400 051

Dear Sirs,

Sub.: Schedule of Investor and Analyst Meet of Jubilant Pharmova Limited

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising Investor and Analyst Meet on June 18, 2021. Details of the same are attached.

This is for information and record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Rajiv Shah
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624



**JUBILANT
PHARMOVA**

Investor & Analyst Meet
18th June 2021

Invite



**JUBILANT PHARMOVA LIMITED CORDIALLY INVITES YOU TO A VIRTUAL INVESTOR & ANALYST MEET,
a platform to discuss business and strategic initiatives with the Company's management**

18th June 2021 | 05:00 PM – 08:00 PM IST

[Registration and log-in link](#)

Agenda



Duration	Topic	Presenter	Designation
3 min	Initial Address	Mr Shyam Bhartia, Mr Hari Bhartia	Chairman and CCMD
3 min	GCFO address	Mr Arvind Chokhany	Group CFO
15 min	Jubilant Pharma, Evolution and Strategy	Mr Pramod Yadav	CEO, Jubilant Pharma
20 min	Radiopharma	Mr Sergio Calvo	President, Radiopharmaceuticals
15 min	Allergy	Mr Chris Preti	President, ABU
15 min	CMO	Mr Amit Arora	President, CMO
15 min	API	Mr Gunjan Singh	Head, API business
15 min	Generics	Mr Terry Fullem Mr Jasdeep Singh	President, Jubilant Cadista Head, Dosage Formulation (Non-US)
3 min	Jubilant Pharma Financials	Mr Christopher Krawstchuk	CFO, Jubilant Pharma
10 min	Contract Research and Development Services	Mr Marcel Velterop	President, Jubilant Biosys
10 min	Proprietary Novel Drugs	Dr Syed Kazmi	CEO, Jubilant Therapeutics
5 min	Jubilant Pharmova Financials	Mr Arun Sharma	CFO, Jubilant Pharmova
45 min	Q&A	Jubilant Pharmova Team	

Thank You

For further information, please contact:

Jubilant Pharmova

Hemant Bakhru/ Pavleen Taneja

E-mail: hemant.bakhru@jubl.com/ pavleen.taneja@jubl.com

CDR India

Siddharth Rangnekar / Karl H Kolah

E-mail: siddharth@cdr-india.com/ karl@cdr-india.com